nodes	percent_of_prediction	percent_of_DWPC	metapath
Sumatriptan—SLCO1A2—Indinavir—acquired immunodeficiency syndrome	0.0551	0.0802	CbGbCtD
Sumatriptan—SLCO1A2—Nelfinavir—acquired immunodeficiency syndrome	0.0535	0.0778	CbGbCtD
Sumatriptan—SLCO1B1—Indinavir—acquired immunodeficiency syndrome	0.052	0.0756	CbGbCtD
Sumatriptan—SLCO1B1—Nelfinavir—acquired immunodeficiency syndrome	0.0505	0.0734	CbGbCtD
Sumatriptan—SLCO1A2—Ritonavir—acquired immunodeficiency syndrome	0.0484	0.0704	CbGbCtD
Sumatriptan—SLCO1A2—Saquinavir—acquired immunodeficiency syndrome	0.0484	0.0704	CbGbCtD
Sumatriptan—SLCO1B1—Saquinavir—acquired immunodeficiency syndrome	0.0456	0.0664	CbGbCtD
Sumatriptan—SLCO1B1—Ritonavir—acquired immunodeficiency syndrome	0.0456	0.0664	CbGbCtD
Sumatriptan—ABCG2—Nelfinavir—acquired immunodeficiency syndrome	0.0401	0.0583	CbGbCtD
Sumatriptan—ABCG2—Ritonavir—acquired immunodeficiency syndrome	0.0363	0.0527	CbGbCtD
Sumatriptan—ABCG2—Saquinavir—acquired immunodeficiency syndrome	0.0363	0.0527	CbGbCtD
Sumatriptan—ABCG2—Zidovudine—acquired immunodeficiency syndrome	0.0348	0.0506	CbGbCtD
Sumatriptan—ABCG2—Lamivudine—acquired immunodeficiency syndrome	0.0269	0.0391	CbGbCtD
Sumatriptan—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0191	0.0278	CbGbCtD
Sumatriptan—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0172	0.0251	CbGbCtD
Sumatriptan—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.0149	0.0217	CbGbCtD
Sumatriptan—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.0145	0.021	CbGbCtD
Sumatriptan—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.0131	0.019	CbGbCtD
Sumatriptan—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.0131	0.019	CbGbCtD
Sumatriptan—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.0125	0.0182	CbGbCtD
Sumatriptan—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.0097	0.0141	CbGbCtD
Sumatriptan—HTR3A—nerve—acquired immunodeficiency syndrome	0.00295	0.0696	CbGeAlD
Sumatriptan—SLCO1B1—blood plasma—acquired immunodeficiency syndrome	0.00216	0.0511	CbGeAlD
Sumatriptan—MAOA—nerve—acquired immunodeficiency syndrome	0.00183	0.0431	CbGeAlD
Sumatriptan—DRD2—nerve—acquired immunodeficiency syndrome	0.00181	0.0426	CbGeAlD
Sumatriptan—HTR1A—blood plasma—acquired immunodeficiency syndrome	0.00151	0.0356	CbGeAlD
Sumatriptan—MAOA—blood plasma—acquired immunodeficiency syndrome	0.00138	0.0326	CbGeAlD
Sumatriptan—HTR1F—nervous system—acquired immunodeficiency syndrome	0.00136	0.0321	CbGeAlD
Sumatriptan—HTR1F—central nervous system—acquired immunodeficiency syndrome	0.00131	0.0309	CbGeAlD
Sumatriptan—HTR1F—brain—acquired immunodeficiency syndrome	0.00104	0.0245	CbGeAlD
Sumatriptan—HTR3A—digestive system—acquired immunodeficiency syndrome	0.000858	0.0202	CbGeAlD
Sumatriptan—SLCO1B1—digestive system—acquired immunodeficiency syndrome	0.000832	0.0196	CbGeAlD
Sumatriptan—HTR3A—blood—acquired immunodeficiency syndrome	0.000818	0.0193	CbGeAlD
Sumatriptan—SLCO1B1—blood—acquired immunodeficiency syndrome	0.000793	0.0187	CbGeAlD
Sumatriptan—MAOA—retina—acquired immunodeficiency syndrome	0.000756	0.0178	CbGeAlD
Sumatriptan—DRD2—retina—acquired immunodeficiency syndrome	0.000748	0.0176	CbGeAlD
Sumatriptan—HTR3A—lung—acquired immunodeficiency syndrome	0.000717	0.0169	CbGeAlD
Sumatriptan—SLCO1A2—digestive system—acquired immunodeficiency syndrome	0.000677	0.016	CbGeAlD
Sumatriptan—HTR3A—nervous system—acquired immunodeficiency syndrome	0.000664	0.0157	CbGeAlD
Sumatriptan—HTR1B—spinal cord—acquired immunodeficiency syndrome	0.000661	0.0156	CbGeAlD
Sumatriptan—HTR3A—central nervous system—acquired immunodeficiency syndrome	0.000639	0.0151	CbGeAlD
Sumatriptan—SLCO1A2—spinal cord—acquired immunodeficiency syndrome	0.000622	0.0147	CbGeAlD
Sumatriptan—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.00059	0.0139	CbGeAlD
Sumatriptan—SLCO1A2—lung—acquired immunodeficiency syndrome	0.000566	0.0133	CbGeAlD
Sumatriptan—HTR1B—nervous system—acquired immunodeficiency syndrome	0.000557	0.0131	CbGeAlD
Sumatriptan—HTR1D—nervous system—acquired immunodeficiency syndrome	0.000539	0.0127	CbGeAlD
Sumatriptan—HTR1B—central nervous system—acquired immunodeficiency syndrome	0.000536	0.0126	CbGeAlD
Sumatriptan—HTR1A—spinal cord—acquired immunodeficiency syndrome	0.000533	0.0126	CbGeAlD
Sumatriptan—MAOA—digestive system—acquired immunodeficiency syndrome	0.000531	0.0125	CbGeAlD
Sumatriptan—SLCO1A2—nervous system—acquired immunodeficiency syndrome	0.000524	0.0124	CbGeAlD
Sumatriptan—HTR1D—central nervous system—acquired immunodeficiency syndrome	0.000519	0.0122	CbGeAlD
Sumatriptan—HTR3A—brain—acquired immunodeficiency syndrome	0.000507	0.012	CbGeAlD
Sumatriptan—MAOA—blood—acquired immunodeficiency syndrome	0.000506	0.0119	CbGeAlD
Sumatriptan—SLCO1A2—central nervous system—acquired immunodeficiency syndrome	0.000504	0.0119	CbGeAlD
Sumatriptan—MAOA—spinal cord—acquired immunodeficiency syndrome	0.000487	0.0115	CbGeAlD
Sumatriptan—MAOA—vagina—acquired immunodeficiency syndrome	0.000469	0.0111	CbGeAlD
Sumatriptan—HTR1A—nervous system—acquired immunodeficiency syndrome	0.000449	0.0106	CbGeAlD
Sumatriptan—MAOA—lung—acquired immunodeficiency syndrome	0.000443	0.0105	CbGeAlD
Sumatriptan—DRD2—lung—acquired immunodeficiency syndrome	0.000438	0.0103	CbGeAlD
Sumatriptan—ABCG2—blood—acquired immunodeficiency syndrome	0.000438	0.0103	CbGeAlD
Sumatriptan—HTR1A—central nervous system—acquired immunodeficiency syndrome	0.000433	0.0102	CbGeAlD
Sumatriptan—HTR1B—brain—acquired immunodeficiency syndrome	0.000426	0.01	CbGeAlD
Sumatriptan—ABCG2—bone marrow—acquired immunodeficiency syndrome	0.000424	0.01	CbGeAlD
Sumatriptan—ABCG2—spinal cord—acquired immunodeficiency syndrome	0.000422	0.00996	CbGeAlD
Sumatriptan—HTR1D—brain—acquired immunodeficiency syndrome	0.000412	0.00972	CbGeAlD
Sumatriptan—MAOA—nervous system—acquired immunodeficiency syndrome	0.000411	0.00968	CbGeAlD
Sumatriptan—ABCG2—vagina—acquired immunodeficiency syndrome	0.000406	0.00959	CbGeAlD
Sumatriptan—DRD2—nervous system—acquired immunodeficiency syndrome	0.000406	0.00958	CbGeAlD
Sumatriptan—SLCO1A2—brain—acquired immunodeficiency syndrome	0.0004	0.00945	CbGeAlD
Sumatriptan—MAOA—central nervous system—acquired immunodeficiency syndrome	0.000395	0.00932	CbGeAlD
Sumatriptan—DRD2—central nervous system—acquired immunodeficiency syndrome	0.000391	0.00922	CbGeAlD
Sumatriptan—ABCG2—lung—acquired immunodeficiency syndrome	0.000384	0.00907	CbGeAlD
Sumatriptan—HTR1A—brain—acquired immunodeficiency syndrome	0.000343	0.0081	CbGeAlD
Sumatriptan—ABCB1—retina—acquired immunodeficiency syndrome	0.000323	0.00762	CbGeAlD
Sumatriptan—MAOA—brain—acquired immunodeficiency syndrome	0.000314	0.0074	CbGeAlD
Sumatriptan—DRD2—brain—acquired immunodeficiency syndrome	0.00031	0.00732	CbGeAlD
Sumatriptan—MAOA—lymph node—acquired immunodeficiency syndrome	0.000303	0.00715	CbGeAlD
Sumatriptan—ABCG2—brain—acquired immunodeficiency syndrome	0.000272	0.00642	CbGeAlD
Sumatriptan—ABCG2—lymph node—acquired immunodeficiency syndrome	0.000263	0.0062	CbGeAlD
Sumatriptan—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.00023	0.00542	CbGeAlD
Sumatriptan—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000227	0.00535	CbGeAlD
Sumatriptan—ABCB1—blood—acquired immunodeficiency syndrome	0.000216	0.0051	CbGeAlD
Sumatriptan—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000209	0.00493	CbGeAlD
Sumatriptan—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000208	0.00491	CbGeAlD
Sumatriptan—ABCB1—vagina—acquired immunodeficiency syndrome	0.0002	0.00473	CbGeAlD
Sumatriptan—ABCB1—lung—acquired immunodeficiency syndrome	0.00019	0.00447	CbGeAlD
Sumatriptan—ABCB1—nervous system—acquired immunodeficiency syndrome	0.000175	0.00414	CbGeAlD
Sumatriptan—ABCB1—central nervous system—acquired immunodeficiency syndrome	0.000169	0.00399	CbGeAlD
Sumatriptan—ABCB1—brain—acquired immunodeficiency syndrome	0.000134	0.00316	CbGeAlD
Sumatriptan—ABCB1—lymph node—acquired immunodeficiency syndrome	0.00013	0.00306	CbGeAlD
Sumatriptan—Syncope—Saquinavir—acquired immunodeficiency syndrome	9.03e-05	0.000366	CcSEcCtD
Sumatriptan—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	9.01e-05	0.000365	CcSEcCtD
Sumatriptan—Tremor—Lamivudine—acquired immunodeficiency syndrome	9e-05	0.000365	CcSEcCtD
Sumatriptan—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	8.98e-05	0.000364	CcSEcCtD
Sumatriptan—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	8.97e-05	0.000363	CcSEcCtD
Sumatriptan—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	8.96e-05	0.000363	CcSEcCtD
Sumatriptan—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	8.95e-05	0.000363	CcSEcCtD
Sumatriptan—Pruritus—Stavudine—acquired immunodeficiency syndrome	8.94e-05	0.000362	CcSEcCtD
Sumatriptan—Asthenia—Abacavir—acquired immunodeficiency syndrome	8.93e-05	0.000362	CcSEcCtD
Sumatriptan—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	8.92e-05	0.000362	CcSEcCtD
Sumatriptan—Ill-defined disorder—Lamivudine—acquired immunodeficiency syndrome	8.91e-05	0.000361	CcSEcCtD
Sumatriptan—Myalgia—Ritonavir—acquired immunodeficiency syndrome	8.9e-05	0.000361	CcSEcCtD
Sumatriptan—Chest pain—Ritonavir—acquired immunodeficiency syndrome	8.9e-05	0.000361	CcSEcCtD
Sumatriptan—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	8.9e-05	0.000361	CcSEcCtD
Sumatriptan—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	8.88e-05	0.00036	CcSEcCtD
Sumatriptan—Anaemia—Lamivudine—acquired immunodeficiency syndrome	8.88e-05	0.00036	CcSEcCtD
Sumatriptan—Anxiety—Ritonavir—acquired immunodeficiency syndrome	8.87e-05	0.00036	CcSEcCtD
Sumatriptan—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	8.85e-05	0.000359	CcSEcCtD
Sumatriptan—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	8.81e-05	0.000357	CcSEcCtD
Sumatriptan—Pruritus—Abacavir—acquired immunodeficiency syndrome	8.8e-05	0.000357	CcSEcCtD
Sumatriptan—Fatigue—Indinavir—acquired immunodeficiency syndrome	8.8e-05	0.000357	CcSEcCtD
Sumatriptan—Discomfort—Ritonavir—acquired immunodeficiency syndrome	8.8e-05	0.000357	CcSEcCtD
Sumatriptan—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	8.79e-05	0.000356	CcSEcCtD
Sumatriptan—Cough—Saquinavir—acquired immunodeficiency syndrome	8.78e-05	0.000356	CcSEcCtD
Sumatriptan—Angioedema—Lamivudine—acquired immunodeficiency syndrome	8.77e-05	0.000356	CcSEcCtD
Sumatriptan—Pain—Indinavir—acquired immunodeficiency syndrome	8.73e-05	0.000354	CcSEcCtD
Sumatriptan—Constipation—Indinavir—acquired immunodeficiency syndrome	8.73e-05	0.000354	CcSEcCtD
Sumatriptan—Urticaria—Zidovudine—acquired immunodeficiency syndrome	8.72e-05	0.000354	CcSEcCtD
Sumatriptan—Convulsion—Saquinavir—acquired immunodeficiency syndrome	8.72e-05	0.000354	CcSEcCtD
Sumatriptan—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	8.71e-05	0.000353	CcSEcCtD
Sumatriptan—Hypertension—Saquinavir—acquired immunodeficiency syndrome	8.69e-05	0.000352	CcSEcCtD
Sumatriptan—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	8.68e-05	0.000352	CcSEcCtD
Sumatriptan—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	8.68e-05	0.000352	CcSEcCtD
Sumatriptan—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	8.67e-05	0.000351	CcSEcCtD
Sumatriptan—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	8.66e-05	0.000351	CcSEcCtD
Sumatriptan—Malaise—Lamivudine—acquired immunodeficiency syndrome	8.66e-05	0.000351	CcSEcCtD
Sumatriptan—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	8.64e-05	0.00035	CcSEcCtD
Sumatriptan—Nausea—Didanosine—acquired immunodeficiency syndrome	8.64e-05	0.00035	CcSEcCtD
Sumatriptan—Vertigo—Lamivudine—acquired immunodeficiency syndrome	8.63e-05	0.00035	CcSEcCtD
Sumatriptan—Hypotension—Delavirdine—acquired immunodeficiency syndrome	8.62e-05	0.00035	CcSEcCtD
Sumatriptan—Syncope—Lamivudine—acquired immunodeficiency syndrome	8.61e-05	0.000349	CcSEcCtD
Sumatriptan—Confusional state—Ritonavir—acquired immunodeficiency syndrome	8.61e-05	0.000349	CcSEcCtD
Sumatriptan—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	8.6e-05	0.000349	CcSEcCtD
Sumatriptan—Somnolence—Efavirenz—acquired immunodeficiency syndrome	8.58e-05	0.000348	CcSEcCtD
Sumatriptan—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	8.57e-05	0.000347	CcSEcCtD
Sumatriptan—Chest pain—Saquinavir—acquired immunodeficiency syndrome	8.57e-05	0.000347	CcSEcCtD
Sumatriptan—Myalgia—Saquinavir—acquired immunodeficiency syndrome	8.57e-05	0.000347	CcSEcCtD
Sumatriptan—Anxiety—Saquinavir—acquired immunodeficiency syndrome	8.54e-05	0.000346	CcSEcCtD
Sumatriptan—Oedema—Ritonavir—acquired immunodeficiency syndrome	8.54e-05	0.000346	CcSEcCtD
Sumatriptan—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	8.51e-05	0.000345	CcSEcCtD
Sumatriptan—Discomfort—Saquinavir—acquired immunodeficiency syndrome	8.47e-05	0.000343	CcSEcCtD
Sumatriptan—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	8.44e-05	0.000342	CcSEcCtD
Sumatriptan—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	8.41e-05	0.000341	CcSEcCtD
Sumatriptan—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	8.41e-05	0.000341	CcSEcCtD
Sumatriptan—Shock—Ritonavir—acquired immunodeficiency syndrome	8.4e-05	0.00034	CcSEcCtD
Sumatriptan—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	8.39e-05	0.00034	CcSEcCtD
Sumatriptan—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	8.38e-05	0.00034	CcSEcCtD
Sumatriptan—Cough—Lamivudine—acquired immunodeficiency syndrome	8.38e-05	0.00034	CcSEcCtD
Sumatriptan—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	8.38e-05	0.00034	CcSEcCtD
Sumatriptan—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	8.37e-05	0.000339	CcSEcCtD
Sumatriptan—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	8.36e-05	0.000339	CcSEcCtD
Sumatriptan—Dizziness—Stavudine—acquired immunodeficiency syndrome	8.35e-05	0.000339	CcSEcCtD
Sumatriptan—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	8.35e-05	0.000339	CcSEcCtD
Sumatriptan—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	8.33e-05	0.000338	CcSEcCtD
Sumatriptan—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	8.33e-05	0.000338	CcSEcCtD
Sumatriptan—Convulsion—Lamivudine—acquired immunodeficiency syndrome	8.32e-05	0.000337	CcSEcCtD
Sumatriptan—Vomiting—Nevirapine—acquired immunodeficiency syndrome	8.32e-05	0.000337	CcSEcCtD
Sumatriptan—Fatigue—Efavirenz—acquired immunodeficiency syndrome	8.32e-05	0.000337	CcSEcCtD
Sumatriptan—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	8.29e-05	0.000336	CcSEcCtD
Sumatriptan—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	8.29e-05	0.000336	CcSEcCtD
Sumatriptan—Confusional state—Saquinavir—acquired immunodeficiency syndrome	8.28e-05	0.000336	CcSEcCtD
Sumatriptan—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	8.25e-05	0.000335	CcSEcCtD
Sumatriptan—Constipation—Efavirenz—acquired immunodeficiency syndrome	8.25e-05	0.000334	CcSEcCtD
Sumatriptan—Pain—Efavirenz—acquired immunodeficiency syndrome	8.25e-05	0.000334	CcSEcCtD
Sumatriptan—Rash—Nevirapine—acquired immunodeficiency syndrome	8.25e-05	0.000334	CcSEcCtD
Sumatriptan—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	8.24e-05	0.000334	CcSEcCtD
Sumatriptan—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	8.23e-05	0.000334	CcSEcCtD
Sumatriptan—Dizziness—Abacavir—acquired immunodeficiency syndrome	8.23e-05	0.000334	CcSEcCtD
Sumatriptan—Oedema—Saquinavir—acquired immunodeficiency syndrome	8.22e-05	0.000333	CcSEcCtD
Sumatriptan—Somnolence—Delavirdine—acquired immunodeficiency syndrome	8.21e-05	0.000333	CcSEcCtD
Sumatriptan—Headache—Nevirapine—acquired immunodeficiency syndrome	8.2e-05	0.000332	CcSEcCtD
Sumatriptan—Myalgia—Lamivudine—acquired immunodeficiency syndrome	8.18e-05	0.000331	CcSEcCtD
Sumatriptan—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	8.18e-05	0.000331	CcSEcCtD
Sumatriptan—Chest pain—Lamivudine—acquired immunodeficiency syndrome	8.18e-05	0.000331	CcSEcCtD
Sumatriptan—Infection—Saquinavir—acquired immunodeficiency syndrome	8.16e-05	0.000331	CcSEcCtD
Sumatriptan—Anxiety—Lamivudine—acquired immunodeficiency syndrome	8.15e-05	0.00033	CcSEcCtD
Sumatriptan—Urticaria—Indinavir—acquired immunodeficiency syndrome	8.11e-05	0.000329	CcSEcCtD
Sumatriptan—Shock—Saquinavir—acquired immunodeficiency syndrome	8.08e-05	0.000328	CcSEcCtD
Sumatriptan—Discomfort—Lamivudine—acquired immunodeficiency syndrome	8.08e-05	0.000327	CcSEcCtD
Sumatriptan—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	8.07e-05	0.000327	CcSEcCtD
Sumatriptan—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	8.07e-05	0.000327	CcSEcCtD
Sumatriptan—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	8.06e-05	0.000327	CcSEcCtD
Sumatriptan—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	8.06e-05	0.000327	CcSEcCtD
Sumatriptan—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	8.04e-05	0.000326	CcSEcCtD
Sumatriptan—Vomiting—Stavudine—acquired immunodeficiency syndrome	8.03e-05	0.000326	CcSEcCtD
Sumatriptan—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	8.02e-05	0.000325	CcSEcCtD
Sumatriptan—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	8e-05	0.000324	CcSEcCtD
Sumatriptan—Rash—Nelfinavir—acquired immunodeficiency syndrome	7.99e-05	0.000324	CcSEcCtD
Sumatriptan—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	7.98e-05	0.000324	CcSEcCtD
Sumatriptan—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	7.98e-05	0.000324	CcSEcCtD
Sumatriptan—Hypotension—Ritonavir—acquired immunodeficiency syndrome	7.98e-05	0.000323	CcSEcCtD
Sumatriptan—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	7.97e-05	0.000323	CcSEcCtD
Sumatriptan—Rash—Stavudine—acquired immunodeficiency syndrome	7.96e-05	0.000323	CcSEcCtD
Sumatriptan—Fatigue—Delavirdine—acquired immunodeficiency syndrome	7.96e-05	0.000323	CcSEcCtD
Sumatriptan—Dermatitis—Stavudine—acquired immunodeficiency syndrome	7.96e-05	0.000323	CcSEcCtD
Sumatriptan—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	7.95e-05	0.000322	CcSEcCtD
Sumatriptan—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	7.94e-05	0.000322	CcSEcCtD
Sumatriptan—Headache—Nelfinavir—acquired immunodeficiency syndrome	7.94e-05	0.000322	CcSEcCtD
Sumatriptan—Headache—Stavudine—acquired immunodeficiency syndrome	7.91e-05	0.000321	CcSEcCtD
Sumatriptan—Vomiting—Abacavir—acquired immunodeficiency syndrome	7.91e-05	0.000321	CcSEcCtD
Sumatriptan—Confusional state—Lamivudine—acquired immunodeficiency syndrome	7.9e-05	0.00032	CcSEcCtD
Sumatriptan—Pain—Delavirdine—acquired immunodeficiency syndrome	7.89e-05	0.00032	CcSEcCtD
Sumatriptan—Constipation—Delavirdine—acquired immunodeficiency syndrome	7.89e-05	0.00032	CcSEcCtD
Sumatriptan—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	7.89e-05	0.00032	CcSEcCtD
Sumatriptan—Asthenia—Zidovudine—acquired immunodeficiency syndrome	7.88e-05	0.000319	CcSEcCtD
Sumatriptan—Rash—Abacavir—acquired immunodeficiency syndrome	7.85e-05	0.000318	CcSEcCtD
Sumatriptan—Dermatitis—Abacavir—acquired immunodeficiency syndrome	7.84e-05	0.000318	CcSEcCtD
Sumatriptan—Oedema—Lamivudine—acquired immunodeficiency syndrome	7.84e-05	0.000318	CcSEcCtD
Sumatriptan—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	7.84e-05	0.000318	CcSEcCtD
Sumatriptan—Headache—Abacavir—acquired immunodeficiency syndrome	7.8e-05	0.000316	CcSEcCtD
Sumatriptan—Infection—Lamivudine—acquired immunodeficiency syndrome	7.79e-05	0.000316	CcSEcCtD
Sumatriptan—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	7.78e-05	0.000315	CcSEcCtD
Sumatriptan—Nausea—Nevirapine—acquired immunodeficiency syndrome	7.77e-05	0.000315	CcSEcCtD
Sumatriptan—Pruritus—Zidovudine—acquired immunodeficiency syndrome	7.77e-05	0.000315	CcSEcCtD
Sumatriptan—Shock—Lamivudine—acquired immunodeficiency syndrome	7.71e-05	0.000313	CcSEcCtD
Sumatriptan—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	7.69e-05	0.000312	CcSEcCtD
Sumatriptan—Hypotension—Saquinavir—acquired immunodeficiency syndrome	7.68e-05	0.000311	CcSEcCtD
Sumatriptan—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	7.67e-05	0.000311	CcSEcCtD
Sumatriptan—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	7.66e-05	0.000311	CcSEcCtD
Sumatriptan—Urticaria—Efavirenz—acquired immunodeficiency syndrome	7.66e-05	0.000311	CcSEcCtD
Sumatriptan—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	7.63e-05	0.000309	CcSEcCtD
Sumatriptan—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	7.63e-05	0.000309	CcSEcCtD
Sumatriptan—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	7.61e-05	0.000309	CcSEcCtD
Sumatriptan—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	7.61e-05	0.000309	CcSEcCtD
Sumatriptan—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	7.61e-05	0.000308	CcSEcCtD
Sumatriptan—Somnolence—Ritonavir—acquired immunodeficiency syndrome	7.59e-05	0.000308	CcSEcCtD
Sumatriptan—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	7.58e-05	0.000307	CcSEcCtD
Sumatriptan—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	7.55e-05	0.000306	CcSEcCtD
Sumatriptan—Nausea—Nelfinavir—acquired immunodeficiency syndrome	7.53e-05	0.000305	CcSEcCtD
Sumatriptan—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	7.52e-05	0.000305	CcSEcCtD
Sumatriptan—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	7.51e-05	0.000305	CcSEcCtD
Sumatriptan—HTR1A—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	7.51e-05	0.00317	CbGpPWpGaD
Sumatriptan—Nausea—Stavudine—acquired immunodeficiency syndrome	7.5e-05	0.000304	CcSEcCtD
Sumatriptan—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	7.48e-05	0.000303	CcSEcCtD
Sumatriptan—HTR1F—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	7.43e-05	0.00314	CbGpPWpGaD
Sumatriptan—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	7.42e-05	0.000301	CcSEcCtD
Sumatriptan—Nausea—Abacavir—acquired immunodeficiency syndrome	7.39e-05	0.0003	CcSEcCtD
Sumatriptan—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	7.38e-05	0.000299	CcSEcCtD
Sumatriptan—ABCB1—Allograft Rejection—IL4—acquired immunodeficiency syndrome	7.37e-05	0.00312	CbGpPWpGaD
Sumatriptan—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	7.37e-05	0.000299	CcSEcCtD
Sumatriptan—Fatigue—Ritonavir—acquired immunodeficiency syndrome	7.36e-05	0.000298	CcSEcCtD
Sumatriptan—HTR1D—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	7.34e-05	0.0031	CbGpPWpGaD
Sumatriptan—Urticaria—Delavirdine—acquired immunodeficiency syndrome	7.33e-05	0.000297	CcSEcCtD
Sumatriptan—Asthenia—Indinavir—acquired immunodeficiency syndrome	7.33e-05	0.000297	CcSEcCtD
Sumatriptan—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	7.32e-05	0.000297	CcSEcCtD
Sumatriptan—Hypotension—Lamivudine—acquired immunodeficiency syndrome	7.32e-05	0.000297	CcSEcCtD
Sumatriptan—Somnolence—Saquinavir—acquired immunodeficiency syndrome	7.3e-05	0.000296	CcSEcCtD
Sumatriptan—Pain—Ritonavir—acquired immunodeficiency syndrome	7.3e-05	0.000296	CcSEcCtD
Sumatriptan—Constipation—Ritonavir—acquired immunodeficiency syndrome	7.3e-05	0.000296	CcSEcCtD
Sumatriptan—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	7.3e-05	0.000296	CcSEcCtD
Sumatriptan—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	7.3e-05	0.000296	CcSEcCtD
Sumatriptan—Dizziness—Zidovudine—acquired immunodeficiency syndrome	7.26e-05	0.000294	CcSEcCtD
Sumatriptan—Pruritus—Indinavir—acquired immunodeficiency syndrome	7.22e-05	0.000293	CcSEcCtD
Sumatriptan—ABCB1—Allograft Rejection—HLA-B—acquired immunodeficiency syndrome	7.21e-05	0.00305	CbGpPWpGaD
Sumatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	7.19e-05	0.00304	CbGpPWpGaD
Sumatriptan—HTR1B—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	7.19e-05	0.00304	CbGpPWpGaD
Sumatriptan—DRD2—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	7.18e-05	0.00304	CbGpPWpGaD
Sumatriptan—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	7.14e-05	0.00029	CcSEcCtD
Sumatriptan—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	7.14e-05	0.00029	CcSEcCtD
Sumatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	7.14e-05	0.00302	CbGpPWpGaD
Sumatriptan—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	7.11e-05	0.000288	CcSEcCtD
Sumatriptan—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	7.09e-05	0.000288	CcSEcCtD
Sumatriptan—Fatigue—Saquinavir—acquired immunodeficiency syndrome	7.08e-05	0.000287	CcSEcCtD
Sumatriptan—HTR3A—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	7.08e-05	0.00299	CbGpPWpGaD
Sumatriptan—HTR1D—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	7.07e-05	0.00299	CbGpPWpGaD
Sumatriptan—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	7.04e-05	0.000285	CcSEcCtD
Sumatriptan—DRD2—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	7.04e-05	0.00298	CbGpPWpGaD
Sumatriptan—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	7.03e-05	0.000285	CcSEcCtD
Sumatriptan—Pain—Saquinavir—acquired immunodeficiency syndrome	7.03e-05	0.000285	CcSEcCtD
Sumatriptan—Constipation—Saquinavir—acquired immunodeficiency syndrome	7.03e-05	0.000285	CcSEcCtD
Sumatriptan—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	6.99e-05	0.000283	CcSEcCtD
Sumatriptan—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	6.99e-05	0.000283	CcSEcCtD
Sumatriptan—Vomiting—Zidovudine—acquired immunodeficiency syndrome	6.98e-05	0.000283	CcSEcCtD
Sumatriptan—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	6.98e-05	0.000283	CcSEcCtD
Sumatriptan—Somnolence—Lamivudine—acquired immunodeficiency syndrome	6.97e-05	0.000282	CcSEcCtD
Sumatriptan—Rash—Zidovudine—acquired immunodeficiency syndrome	6.92e-05	0.000281	CcSEcCtD
Sumatriptan—Asthenia—Efavirenz—acquired immunodeficiency syndrome	6.92e-05	0.000281	CcSEcCtD
Sumatriptan—HTR1B—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	6.92e-05	0.00293	CbGpPWpGaD
Sumatriptan—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	6.92e-05	0.00028	CcSEcCtD
Sumatriptan—Headache—Zidovudine—acquired immunodeficiency syndrome	6.88e-05	0.000279	CcSEcCtD
Sumatriptan—Pruritus—Efavirenz—acquired immunodeficiency syndrome	6.83e-05	0.000277	CcSEcCtD
Sumatriptan—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	6.81e-05	0.000276	CcSEcCtD
Sumatriptan—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	6.8e-05	0.000276	CcSEcCtD
Sumatriptan—Urticaria—Ritonavir—acquired immunodeficiency syndrome	6.78e-05	0.000275	CcSEcCtD
Sumatriptan—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	6.77e-05	0.000274	CcSEcCtD
Sumatriptan—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	6.77e-05	0.000274	CcSEcCtD
Sumatriptan—Fatigue—Lamivudine—acquired immunodeficiency syndrome	6.76e-05	0.000274	CcSEcCtD
Sumatriptan—Dizziness—Indinavir—acquired immunodeficiency syndrome	6.75e-05	0.000274	CcSEcCtD
Sumatriptan—DRD2—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	6.75e-05	0.00286	CbGpPWpGaD
Sumatriptan—DRD2—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	6.75e-05	0.00286	CbGpPWpGaD
Sumatriptan—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	6.75e-05	0.000274	CcSEcCtD
Sumatriptan—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	6.75e-05	0.000274	CcSEcCtD
Sumatriptan—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	6.72e-05	0.000272	CcSEcCtD
Sumatriptan—Pain—Lamivudine—acquired immunodeficiency syndrome	6.7e-05	0.000272	CcSEcCtD
Sumatriptan—Constipation—Lamivudine—acquired immunodeficiency syndrome	6.7e-05	0.000272	CcSEcCtD
Sumatriptan—HTR1F—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	6.69e-05	0.00283	CbGpPWpGaD
Sumatriptan—DRD2—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	6.66e-05	0.00282	CbGpPWpGaD
Sumatriptan—HTR1D—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	6.64e-05	0.00281	CbGpPWpGaD
Sumatriptan—Asthenia—Delavirdine—acquired immunodeficiency syndrome	6.62e-05	0.000269	CcSEcCtD
Sumatriptan—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	6.6e-05	0.000268	CcSEcCtD
Sumatriptan—DRD2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	6.59e-05	0.00279	CbGpPWpGaD
Sumatriptan—HTR1D—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	6.56e-05	0.00277	CbGpPWpGaD
Sumatriptan—Pruritus—Delavirdine—acquired immunodeficiency syndrome	6.53e-05	0.000265	CcSEcCtD
Sumatriptan—Urticaria—Saquinavir—acquired immunodeficiency syndrome	6.53e-05	0.000265	CcSEcCtD
Sumatriptan—Nausea—Zidovudine—acquired immunodeficiency syndrome	6.52e-05	0.000264	CcSEcCtD
Sumatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	6.5e-05	0.00275	CbGpPWpGaD
Sumatriptan—HTR1B—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	6.5e-05	0.00275	CbGpPWpGaD
Sumatriptan—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	6.49e-05	0.000263	CcSEcCtD
Sumatriptan—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	6.49e-05	0.000263	CcSEcCtD
Sumatriptan—Vomiting—Indinavir—acquired immunodeficiency syndrome	6.49e-05	0.000263	CcSEcCtD
Sumatriptan—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	6.46e-05	0.000262	CcSEcCtD
Sumatriptan—Rash—Indinavir—acquired immunodeficiency syndrome	6.44e-05	0.000261	CcSEcCtD
Sumatriptan—Dermatitis—Indinavir—acquired immunodeficiency syndrome	6.43e-05	0.000261	CcSEcCtD
Sumatriptan—HTR1B—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	6.42e-05	0.00272	CbGpPWpGaD
Sumatriptan—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	6.41e-05	0.00026	CcSEcCtD
Sumatriptan—Headache—Indinavir—acquired immunodeficiency syndrome	6.4e-05	0.000259	CcSEcCtD
Sumatriptan—Dizziness—Efavirenz—acquired immunodeficiency syndrome	6.38e-05	0.000259	CcSEcCtD
Sumatriptan—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	6.32e-05	0.000256	CcSEcCtD
Sumatriptan—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	6.31e-05	0.00267	CbGpPWpGaD
Sumatriptan—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	6.29e-05	0.000255	CcSEcCtD
Sumatriptan—DRD2—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	6.27e-05	0.00265	CbGpPWpGaD
Sumatriptan—HTR1D—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	6.24e-05	0.00264	CbGpPWpGaD
Sumatriptan—HTR1D—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	6.24e-05	0.00264	CbGpPWpGaD
Sumatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	6.24e-05	0.00264	CbGpPWpGaD
Sumatriptan—Urticaria—Lamivudine—acquired immunodeficiency syndrome	6.23e-05	0.000252	CcSEcCtD
Sumatriptan—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	6.2e-05	0.000251	CcSEcCtD
Sumatriptan—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	6.2e-05	0.000251	CcSEcCtD
Sumatriptan—Vomiting—Efavirenz—acquired immunodeficiency syndrome	6.13e-05	0.000249	CcSEcCtD
Sumatriptan—Asthenia—Ritonavir—acquired immunodeficiency syndrome	6.12e-05	0.000248	CcSEcCtD
Sumatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	6.11e-05	0.00259	CbGpPWpGaD
Sumatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	6.11e-05	0.00259	CbGpPWpGaD
Sumatriptan—HTR1B—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	6.11e-05	0.00258	CbGpPWpGaD
Sumatriptan—HTR1B—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	6.11e-05	0.00258	CbGpPWpGaD
Sumatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	6.11e-05	0.00258	CbGpPWpGaD
Sumatriptan—Dizziness—Delavirdine—acquired immunodeficiency syndrome	6.1e-05	0.000247	CcSEcCtD
Sumatriptan—HTR1D—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	6.1e-05	0.00258	CbGpPWpGaD
Sumatriptan—Rash—Efavirenz—acquired immunodeficiency syndrome	6.08e-05	0.000247	CcSEcCtD
Sumatriptan—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	6.08e-05	0.000246	CcSEcCtD
Sumatriptan—Nausea—Indinavir—acquired immunodeficiency syndrome	6.06e-05	0.000246	CcSEcCtD
Sumatriptan—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	6.05e-05	0.000245	CcSEcCtD
Sumatriptan—Headache—Efavirenz—acquired immunodeficiency syndrome	6.04e-05	0.000245	CcSEcCtD
Sumatriptan—Pruritus—Ritonavir—acquired immunodeficiency syndrome	6.04e-05	0.000245	CcSEcCtD
Sumatriptan—SLCO1A2—Metabolism—TAT—acquired immunodeficiency syndrome	6e-05	0.00254	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	5.97e-05	0.00253	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	5.95e-05	0.00251	CbGpPWpGaD
Sumatriptan—Asthenia—Saquinavir—acquired immunodeficiency syndrome	5.89e-05	0.000239	CcSEcCtD
Sumatriptan—HTR1F—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.89e-05	0.00249	CbGpPWpGaD
Sumatriptan—Vomiting—Delavirdine—acquired immunodeficiency syndrome	5.87e-05	0.000238	CcSEcCtD
Sumatriptan—HTR1F—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	5.87e-05	0.00248	CbGpPWpGaD
Sumatriptan—HTR1A—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	5.85e-05	0.00247	CbGpPWpGaD
Sumatriptan—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	5.84e-05	0.000237	CcSEcCtD
Sumatriptan—HTR1B—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	5.82e-05	0.00246	CbGpPWpGaD
Sumatriptan—Rash—Delavirdine—acquired immunodeficiency syndrome	5.82e-05	0.000236	CcSEcCtD
Sumatriptan—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	5.81e-05	0.000236	CcSEcCtD
Sumatriptan—Pruritus—Saquinavir—acquired immunodeficiency syndrome	5.81e-05	0.000236	CcSEcCtD
Sumatriptan—Headache—Delavirdine—acquired immunodeficiency syndrome	5.78e-05	0.000234	CcSEcCtD
Sumatriptan—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	5.77e-05	0.000234	CcSEcCtD
Sumatriptan—Nausea—Efavirenz—acquired immunodeficiency syndrome	5.73e-05	0.000232	CcSEcCtD
Sumatriptan—HTR3A—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	5.71e-05	0.00242	CbGpPWpGaD
Sumatriptan—DRD2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	5.71e-05	0.00241	CbGpPWpGaD
Sumatriptan—Dizziness—Ritonavir—acquired immunodeficiency syndrome	5.64e-05	0.000229	CcSEcCtD
Sumatriptan—HTR1F—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.63e-05	0.00238	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.63e-05	0.00238	CbGpPWpGaD
Sumatriptan—Asthenia—Lamivudine—acquired immunodeficiency syndrome	5.62e-05	0.000228	CcSEcCtD
Sumatriptan—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	5.62e-05	0.000228	CcSEcCtD
Sumatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	5.62e-05	0.00238	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—TAT—acquired immunodeficiency syndrome	5.56e-05	0.00235	CbGpPWpGaD
Sumatriptan—Pruritus—Lamivudine—acquired immunodeficiency syndrome	5.54e-05	0.000225	CcSEcCtD
Sumatriptan—HTR1F—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	5.52e-05	0.00233	CbGpPWpGaD
Sumatriptan—HTR1F—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	5.52e-05	0.00233	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	5.51e-05	0.00233	CbGpPWpGaD
Sumatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	5.5e-05	0.00233	CbGpPWpGaD
Sumatriptan—Nausea—Delavirdine—acquired immunodeficiency syndrome	5.48e-05	0.000222	CcSEcCtD
Sumatriptan—HTR1A—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	5.48e-05	0.00232	CbGpPWpGaD
Sumatriptan—Dizziness—Saquinavir—acquired immunodeficiency syndrome	5.43e-05	0.00022	CcSEcCtD
Sumatriptan—Vomiting—Ritonavir—acquired immunodeficiency syndrome	5.43e-05	0.00022	CcSEcCtD
Sumatriptan—HTR1B—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	5.4e-05	0.00228	CbGpPWpGaD
Sumatriptan—Rash—Ritonavir—acquired immunodeficiency syndrome	5.38e-05	0.000218	CcSEcCtD
Sumatriptan—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	5.38e-05	0.000218	CcSEcCtD
Sumatriptan—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	5.37e-05	0.00227	CbGpPWpGaD
Sumatriptan—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	5.37e-05	0.00227	CbGpPWpGaD
Sumatriptan—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	5.36e-05	0.000217	CcSEcCtD
Sumatriptan—Headache—Ritonavir—acquired immunodeficiency syndrome	5.35e-05	0.000217	CcSEcCtD
Sumatriptan—HTR1F—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	5.33e-05	0.00225	CbGpPWpGaD
Sumatriptan—HTR1A—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	5.27e-05	0.00223	CbGpPWpGaD
Sumatriptan—Vomiting—Saquinavir—acquired immunodeficiency syndrome	5.22e-05	0.000212	CcSEcCtD
Sumatriptan—Dizziness—Lamivudine—acquired immunodeficiency syndrome	5.18e-05	0.00021	CcSEcCtD
Sumatriptan—Rash—Saquinavir—acquired immunodeficiency syndrome	5.18e-05	0.00021	CcSEcCtD
Sumatriptan—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	5.18e-05	0.00021	CcSEcCtD
Sumatriptan—Headache—Saquinavir—acquired immunodeficiency syndrome	5.15e-05	0.000209	CcSEcCtD
Sumatriptan—DRD2—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	5.14e-05	0.00217	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—TAT—acquired immunodeficiency syndrome	5.13e-05	0.00217	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	5.1e-05	0.00216	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	5.09e-05	0.00215	CbGpPWpGaD
Sumatriptan—Nausea—Ritonavir—acquired immunodeficiency syndrome	5.07e-05	0.000206	CcSEcCtD
Sumatriptan—HTR1F—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	5.01e-05	0.00212	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	5.01e-05	0.00212	CbGpPWpGaD
Sumatriptan—Vomiting—Lamivudine—acquired immunodeficiency syndrome	4.98e-05	0.000202	CcSEcCtD
Sumatriptan—HTR1A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	4.95e-05	0.00209	CbGpPWpGaD
Sumatriptan—Rash—Lamivudine—acquired immunodeficiency syndrome	4.94e-05	0.0002	CcSEcCtD
Sumatriptan—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	4.94e-05	0.0002	CcSEcCtD
Sumatriptan—Headache—Lamivudine—acquired immunodeficiency syndrome	4.91e-05	0.000199	CcSEcCtD
Sumatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	4.89e-05	0.00207	CbGpPWpGaD
Sumatriptan—Nausea—Saquinavir—acquired immunodeficiency syndrome	4.88e-05	0.000198	CcSEcCtD
Sumatriptan—DRD2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	4.81e-05	0.00203	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—TAT—acquired immunodeficiency syndrome	4.75e-05	0.00201	CbGpPWpGaD
Sumatriptan—HTR1D—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	4.75e-05	0.00201	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—AGPS—acquired immunodeficiency syndrome	4.73e-05	0.002	CbGpPWpGaD
Sumatriptan—HTR1A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	4.66e-05	0.00197	CbGpPWpGaD
Sumatriptan—HTR1A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	4.66e-05	0.00197	CbGpPWpGaD
Sumatriptan—Nausea—Lamivudine—acquired immunodeficiency syndrome	4.66e-05	0.000189	CcSEcCtD
Sumatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	4.65e-05	0.00197	CbGpPWpGaD
Sumatriptan—HTR1B—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	4.65e-05	0.00197	CbGpPWpGaD
Sumatriptan—DRD2—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	4.63e-05	0.00196	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	4.55e-05	0.00192	CbGpPWpGaD
Sumatriptan—ABCB1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	4.45e-05	0.00188	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	4.43e-05	0.00188	CbGpPWpGaD
Sumatriptan—SLCO1A2—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	4.4e-05	0.00186	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—AGPS—acquired immunodeficiency syndrome	4.36e-05	0.00185	CbGpPWpGaD
Sumatriptan—DRD2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	4.35e-05	0.00184	CbGpPWpGaD
Sumatriptan—DRD2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	4.29e-05	0.00182	CbGpPWpGaD
Sumatriptan—HTR1D—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.28e-05	0.00181	CbGpPWpGaD
Sumatriptan—HTR1F—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	4.2e-05	0.00177	CbGpPWpGaD
Sumatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	4.19e-05	0.00177	CbGpPWpGaD
Sumatriptan—HTR1B—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.19e-05	0.00177	CbGpPWpGaD
Sumatriptan—HTR1F—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	4.13e-05	0.00175	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	4.11e-05	0.00174	CbGpPWpGaD
Sumatriptan—DRD2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	4.09e-05	0.00173	CbGpPWpGaD
Sumatriptan—DRD2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	4.09e-05	0.00173	CbGpPWpGaD
Sumatriptan—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	4.08e-05	0.00173	CbGpPWpGaD
Sumatriptan—HTR3A—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	4.05e-05	0.00171	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—AGPS—acquired immunodeficiency syndrome	4.04e-05	0.00171	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	3.99e-05	0.00169	CbGpPWpGaD
Sumatriptan—ABCB1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	3.96e-05	0.00167	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	3.89e-05	0.00165	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.81e-05	0.00161	CbGpPWpGaD
Sumatriptan—HTR1F—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.78e-05	0.0016	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.77e-05	0.00159	CbGpPWpGaD
Sumatriptan—SLCO1B1—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	3.76e-05	0.00159	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.75e-05	0.00159	CbGpPWpGaD
Sumatriptan—HTR1D—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.75e-05	0.00159	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.69e-05	0.00156	CbGpPWpGaD
Sumatriptan—DRD2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	3.68e-05	0.00156	CbGpPWpGaD
Sumatriptan—HTR1B—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.67e-05	0.00155	CbGpPWpGaD
Sumatriptan—MAOA—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	3.62e-05	0.00153	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	3.61e-05	0.00153	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.6e-05	0.00152	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.6e-05	0.00152	CbGpPWpGaD
Sumatriptan—HTR1A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	3.54e-05	0.0015	CbGpPWpGaD
Sumatriptan—HTR1D—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.53e-05	0.00149	CbGpPWpGaD
Sumatriptan—HTR1D—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.53e-05	0.00149	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.53e-05	0.00149	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.53e-05	0.00149	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.48e-05	0.00147	CbGpPWpGaD
Sumatriptan—HTR1B—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.45e-05	0.00146	CbGpPWpGaD
Sumatriptan—HTR1B—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.45e-05	0.00146	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.43e-05	0.00145	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.41e-05	0.00144	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.34e-05	0.00141	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.26e-05	0.00138	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.2e-05	0.00135	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.2e-05	0.00135	CbGpPWpGaD
Sumatriptan—HTR1A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	3.19e-05	0.00135	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.19e-05	0.00135	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.15e-05	0.00133	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.14e-05	0.00133	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.14e-05	0.00133	CbGpPWpGaD
Sumatriptan—DRD2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	3.11e-05	0.00132	CbGpPWpGaD
Sumatriptan—HTR1A—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	3.08e-05	0.0013	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.96e-05	0.00125	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.96e-05	0.00125	CbGpPWpGaD
Sumatriptan—MAOA—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	2.92e-05	0.00124	CbGpPWpGaD
Sumatriptan—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	2.88e-05	0.00122	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	2.81e-05	0.00119	CbGpPWpGaD
Sumatriptan—DRD2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.8e-05	0.00118	CbGpPWpGaD
Sumatriptan—HTR1A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	2.8e-05	0.00118	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.69e-05	0.00114	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.69e-05	0.00114	CbGpPWpGaD
Sumatriptan—HTR1D—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.68e-05	0.00113	CbGpPWpGaD
Sumatriptan—HTR1D—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.64e-05	0.00112	CbGpPWpGaD
Sumatriptan—HTR1A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	2.63e-05	0.00111	CbGpPWpGaD
Sumatriptan—HTR1A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	2.63e-05	0.00111	CbGpPWpGaD
Sumatriptan—HTR1B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.63e-05	0.00111	CbGpPWpGaD
Sumatriptan—HTR1B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.59e-05	0.00109	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	2.57e-05	0.00109	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.54e-05	0.00107	CbGpPWpGaD
Sumatriptan—HTR1A—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	2.48e-05	0.00105	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	2.47e-05	0.00104	CbGpPWpGaD
Sumatriptan—DRD2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	2.46e-05	0.00104	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.44e-05	0.00103	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.43e-05	0.00103	CbGpPWpGaD
Sumatriptan—HTR1D—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.42e-05	0.00102	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.4e-05	0.00102	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.39e-05	0.00101	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.39e-05	0.00101	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.39e-05	0.00101	CbGpPWpGaD
Sumatriptan—HTR1B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.37e-05	0.001	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.36e-05	0.000998	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.36e-05	0.000998	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.35e-05	0.000994	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	2.35e-05	0.000994	CbGpPWpGaD
Sumatriptan—DRD2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	2.31e-05	0.000977	CbGpPWpGaD
Sumatriptan—DRD2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	2.31e-05	0.000977	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.25e-05	0.000952	CbGpPWpGaD
Sumatriptan—SLCO1A2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	2.23e-05	0.000945	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.23e-05	0.000944	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.23e-05	0.000941	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.22e-05	0.000938	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.2e-05	0.000928	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	2.18e-05	0.000924	CbGpPWpGaD
Sumatriptan—HTR1F—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.18e-05	0.000924	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.18e-05	0.000922	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.15e-05	0.000909	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.13e-05	0.000902	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.1e-05	0.000887	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.1e-05	0.000887	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.03e-05	0.000858	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.01e-05	0.000851	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	2.01e-05	0.00085	CbGpPWpGaD
Sumatriptan—HTR1A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2e-05	0.000847	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.98e-05	0.000839	CbGpPWpGaD
Sumatriptan—HTR1A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.97e-05	0.000834	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.97e-05	0.000833	CbGpPWpGaD
Sumatriptan—SLCO1B1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.91e-05	0.000808	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.89e-05	0.0008	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.89e-05	0.0008	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.85e-05	0.000784	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.85e-05	0.000784	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.82e-05	0.000769	CbGpPWpGaD
Sumatriptan—HTR1A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.8e-05	0.000763	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.79e-05	0.000757	CbGpPWpGaD
Sumatriptan—DRD2—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	1.78e-05	0.000753	CbGpPWpGaD
Sumatriptan—ABCG2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.77e-05	0.000748	CbGpPWpGaD
Sumatriptan—DRD2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.76e-05	0.000743	CbGpPWpGaD
Sumatriptan—DRD2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.73e-05	0.000732	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.66e-05	0.000702	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.64e-05	0.000693	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.6e-05	0.000675	CbGpPWpGaD
Sumatriptan—DRD2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.58e-05	0.00067	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.57e-05	0.000665	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.5e-05	0.000635	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.46e-05	0.000616	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.44e-05	0.000609	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.44e-05	0.000608	CbGpPWpGaD
Sumatriptan—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	1.42e-05	0.000602	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.42e-05	0.0006	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.41e-05	0.000597	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.41e-05	0.000597	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.41e-05	0.000596	CbGpPWpGaD
Sumatriptan—HTR1D—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.4e-05	0.000591	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.39e-05	0.000587	CbGpPWpGaD
Sumatriptan—HTR1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.37e-05	0.000578	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.32e-05	0.000557	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.3e-05	0.000548	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.27e-05	0.000537	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.27e-05	0.000536	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.24e-05	0.000525	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.24e-05	0.000524	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.24e-05	0.000524	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.17e-05	0.000496	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.17e-05	0.000493	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.07e-05	0.000454	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.06e-05	0.000447	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism—ALB—acquired immunodeficiency syndrome	1.05e-05	0.000443	CbGpPWpGaD
Sumatriptan—HTR1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.04e-05	0.000441	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—ALB—acquired immunodeficiency syndrome	9.7e-06	0.00041	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.67e-06	0.000409	CbGpPWpGaD
Sumatriptan—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	9.56e-06	0.000405	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9.46e-06	0.0004	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.43e-06	0.000399	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.29e-06	0.000393	CbGpPWpGaD
Sumatriptan—DRD2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	9.15e-06	0.000387	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—ALB—acquired immunodeficiency syndrome	8.95e-06	0.000378	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.49e-06	0.000359	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	8.31e-06	0.000351	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—ALB—acquired immunodeficiency syndrome	8.29e-06	0.00035	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.49e-06	0.000317	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.46e-06	0.000315	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.34e-06	0.00031	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.3e-06	0.000309	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.89e-06	0.000291	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.59e-06	0.000236	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.56e-06	0.000235	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.91e-06	0.000208	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.88e-06	0.000207	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	4.48e-06	0.000189	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.4e-06	0.000186	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.31e-06	0.000182	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.29e-06	0.000139	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.88e-06	0.000122	CbGpPWpGaD
